Trial reportTherapeutic advances in respiratory disease
Tolerability of inhaled N-chlorotaurine in humans: a double-blind randomized phase I clinical study.
Trial report in Therapeutic advances in respiratory disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 27 citations in OpenAlex.
- Inhalation of N-Chlorotaurine Is an Effective Treatment of <italic>Aspergillus fumigatus</italic> Pneumonia in Mice.Journal of innate immunity · 2026Article
- Haloamines of the Neurotransmitter γ-Aminobutyric Acid (GABA) and Its Ethyl Ester: Mild Oxidants for Reactions in Hydrophobic Microenvironments and Bactericidal Activity.Molecules (Basel, Switzerland) · 2025Article
- N-chlorotaurine does not alter structural tendon properties: a comparative biomechanical study.Archives of orthopaedic and trauma surgery · 2025Article
- Tolerability of N-chlorotaurine in comparison with routinely used antiseptics: an in vitro study on chondrocytes.Pharmacological reports : PR · 2024Article
- Activity ofInternational journal of molecular sciences · 2024Article
- N-chlorotaurine is highly active against respiratory viruses including SARS-CoV-2 (COVID-19)Emerging microbes & infections · 2022Article
- Comparative Fungicidal Activities of N-Chlorotaurine and Conventional Antiseptics againstJournal of fungi (Basel, Switzerland) · 2022Article
- Efficacy of Inhaled N-Chlorotaurine in a Mouse Model ofJournal of fungi (Basel, Switzerland) · 2022Article
- Taurine and N-Bromotaurine in Topical Treatment of Psoriasis.Advances in experimental medicine and biology · 2022Article
- N-chlorotaurine, a potent weapon against multiresistant bacteria.Journal of applied microbiology · 2021Article
- Activity ofAntibiotics (Basel, Switzerland) · 2021Article
- Is fighting against COVID-19 enough?Scandinavian journal of public health · 2021Article
- Successful treatment of a unique chronic multi-bacterial scalp infection withAccess microbiology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundN-chlorotaurine (NCT), a long-lived oxidant produced by human leukocytes, can be synthesized chemically and used topically as a well-tolerated antiseptic to different body regions including sensitive ones. The aim of this study was to test the tolerability of inhaled 1% NCT in aqueous solution upon repeated application.
methodsThe study was performed double-blind and randomized with a parallel test group (1% NCT) and control group (0.9% NaCl as placebo). There were two Austrian centres involved, the hospitals, Natters and Vöcklabruck. Healthy, full age volunteers were included, 12 in each centre. A total of 12 patients were treated with NCT, and 12 with placebo, exactly half of each group from each centre. The single dose was 1.2 ml inhaled over a period of 10 min using an AKITA JET nebulizer. One inhalation was done every day for five consecutive days. The primary criterion of evaluation was the forced expiratory volume in 1 second (FEV
resultsAll included 15 females and 9 males completed the treatment and the control examinations according to the study protocol. FEV
conclusionsInhaled NCT is well tolerated as in other applications of different body regions. Side effects are mild, topical and transitory. The study was registered prospectively in the European Clinical Trials Database of the European Medicines Agency. The EudraCT number is 2012-003700-12.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.